Schizophrenia News

The FDA has approved an 80-mg capsule of Ingrezza for treatment of tardive dyskinesia in adults, according to a manufacturer-issued press release.

Mental Illness Awareness Week takes place from October 1 to 7.

Galen US recently announced acquisition of U.S. commercial rights to Adasuve, an orally inhaled form of loxapine, from Alexza Pharmaceuticals for agitation associated with schizophrenia or bipolar I disorder.

NEW ORLEANS — Switching from monthly Invega Sustenna to Aristada reduced schizophrenia symptoms among individuals with inadequate response or intolerance to Invega Sustenna, according to data presented at Psych Congress.

Compared with the general population, those with severe mental illness have a substantially increased risk for CVD, according to findings recently published in World Psychiatry.

NEW ORLEANS — Rexulti, a serotonin-dopamine activity modulator, may help individuals with schizophrenia achieve sustained long-term remission, according to data presented at Psych Congress.

NEW ORLEANS — In a session here at Psych Congress, Vijay Gupta, MM, director of Street Symphony and violinist, illustrated the power of music in mental health and homelessness.

The 30th annual Psych Congress will take place in New Orleans from Saturday, Sept. 16 through Tuesday, Sept. 19.

Findings presented at the European College of Neuropsychopharmacology Congress suggested that adjunctive benzodiazepine and antidepressant treatment did not affect cognition nor explain cognitive effects of antipsychotics in midlife schizophrenia.

Digital cognitive-behavioral therapy for insomnia significantly improved insomnia, hallucinations and paranoia among university students with insomnia, according to recent findings.